Neuphoria Therapeutics Inc.
NEUP
$4.84
-$0.11-2.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4,347.65% | -- | -- | -92.72% | -92.15% |
| Total Other Revenue | -7.89% | -112.67% | -24,025.00% | -104.46% | -102.15% |
| Total Revenue | 739.23% | -112.67% | -24,025.00% | -104.26% | -102.05% |
| Cost of Revenue | 29.26% | -106.99% | -17.12% | -114.29% | -115.05% |
| Gross Profit | 2.60% | 106.54% | -314.88% | 118.89% | 121.03% |
| SG&A Expenses | -20.88% | -12.87% | 4.35% | 48.01% | 126.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.34% | -24.11% | -14.06% | 0.26% | 15.62% |
| Operating Income | 27.28% | 23.83% | 13.62% | -12.80% | -51.28% |
| Income Before Tax | 60.23% | 49.30% | 28.27% | 6.22% | -19.94% |
| Income Tax Expenses | 1.22% | -32.66% | 37.88% | 18.35% | 0.00% |
| Earnings from Continuing Operations | 60.63% | 49.83% | 28.21% | 6.13% | -20.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.63% | 49.83% | 28.21% | 6.13% | -20.10% |
| EBIT | 27.28% | 23.83% | 13.62% | -12.80% | -51.28% |
| EBITDA | 27.81% | 24.30% | 13.87% | -14.03% | -54.26% |
| EPS Basic | 76.76% | -37,335.21% | -36,332.88% | -40,519.08% | -45,395.73% |
| Normalized Basic EPS | 77.06% | -37,951.14% | -36,719.78% | -41,275.31% | -46,456.94% |
| EPS Diluted | 76.76% | -37,335.21% | -36,332.88% | -37,372.54% | -38,194.96% |
| Normalized Diluted EPS | 77.06% | -37,951.14% | -36,719.78% | -41,275.31% | -46,456.94% |
| Average Basic Shares Outstanding | 40.99% | 9.37% | -10.26% | -17.02% | -23.52% |
| Average Diluted Shares Outstanding | 40.99% | 9.37% | -10.26% | -17.02% | -23.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
